Plastic surgery popularity gains
This article was originally published in The Rose Sheet
Executive Summary
Surgical and non-surgical activity rose 27% in 2007, American Academy of Facial Plastic and Reconstructive Surgery reports. AAFPRS members say men are increasingly willing to go under the knife, with 30% of the increase attributed to men and 26% to women. However, women still make up 81% of all surgical procedures and 82% of non-surgical procedures performed. Interest in plastic surgery also crosses ethnic lines: African-American cosmetic surgical patients grew by 40% over the past eight years, compared with a 19% increase among Hispanics, a 7% jump among Caucasians, and an 8% decrease among Asian-American patients. According to The Benchmarking Company, heightened interest in plastic surgery has opened up the market for topical skin-care products that complement aesthetic procedures (1"The Rose Sheet" July 30, 2007, p. 5). In particular, rise of non-invasive surgical options, like Botox or hyaluronic acid injections, bodes well for results-driven personal-care products, according to Datamonitor (2"The Rose Sheet" Feb. 25, 2008, p. 4)...
You may also be interested in...
Preference For Convenient Surgical Options Bodes Well For Personal Care
The rapid growth of minimally invasive procedures within the cosmetic surgery ambit signals a prioritization of convenience that bodes well for high-end, results-driven personal-care products, according to Datamonitor
Today’s Beauty Market: From Sampling Campaigns To Surgery Complements
Success in today's beauty market may come easier to firms that embrace innovative sampling, address problems above and below the neck, take up a new attitude about sun care and launch personal-care products that complement surgical procedures, according to industry veteran Alisa Marie Beyer
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.